222 related articles for article (PubMed ID: 21900190)
1. Inhibition of IL-32 activation by α-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model.
Marcondes AM; Li X; Tabellini L; Bartenstein M; Kabacka J; Sale GE; Hansen JA; Dinarello CA; Deeg HJ
Blood; 2011 Nov; 118(18):5031-9. PubMed ID: 21900190
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation.
Tawara I; Sun Y; Lewis EC; Toubai T; Evers R; Nieves E; Azam T; Dinarello CA; Reddy P
Proc Natl Acad Sci U S A; 2012 Jan; 109(2):564-9. PubMed ID: 22203983
[TBL] [Abstract][Full Text] [Related]
4. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
5. Host conditioning is a primary determinant in modulating the effect of IL-7 on murine graft-versus-host disease.
Gendelman M; Hecht T; Logan B; Vodanovic-Jankovic S; Komorowski R; Drobyski WR
J Immunol; 2004 Mar; 172(5):3328-36. PubMed ID: 14978141
[TBL] [Abstract][Full Text] [Related]
6. Idiopathic pneumonia syndrome in mice after allogeneic bone marrow transplantation.
Shankar G; Bryson JS; Jennings CD; Morris PE; Cohen DA
Am J Respir Cell Mol Biol; 1998 Feb; 18(2):235-42. PubMed ID: 9476911
[TBL] [Abstract][Full Text] [Related]
7. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
[TBL] [Abstract][Full Text] [Related]
8. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
9. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease.
Le HT; Keslar K; Nguyen QT; Blazar BR; Hamilton BK; Min B
Front Immunol; 2020; 11():181. PubMed ID: 32117306
[TBL] [Abstract][Full Text] [Related]
11. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
Li JM; Gorechlad J; Larsen CP; Waller EK
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation.
Antin JH; Weisdorf D; Neuberg D; Nicklow R; Clouthier S; Lee SJ; Alyea E; McGarigle C; Blazar BR; Sonis S; Soiffer RJ; Ferrara JL
Blood; 2002 Nov; 100(10):3479-82. PubMed ID: 12393661
[TBL] [Abstract][Full Text] [Related]
13. Treatment with a rho kinase inhibitor improves survival from graft-versus-host disease in mice after MHC-haploidentical hematopoietic cell transplantation.
Iyengar S; Zhan C; Lu J; Korngold R; Schwartz DH
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1104-11. PubMed ID: 24796280
[TBL] [Abstract][Full Text] [Related]
14. α-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics.
Marcondes AM; Karoopongse E; Lesnikova M; Margineantu D; Welte T; Dinarello CA; Hockenbery D; Janciauskiene S; Deeg HJ
Blood; 2014 Oct; 124(18):2881-91. PubMed ID: 25224412
[TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of T helper 1, T helper 2, and inflammatory cytokine expression in patients after allogeneic bone marrow transplantation: relationship with the occurrence of acute graft-versus-host disease.
Carayol G; Bourhis JH; Guillard M; Bosq J; Pailler C; Castagna L; Vernant JP; Pico JL; Hayat M; Chouaib S; Caignard A
Transplantation; 1997 May; 63(9):1307-13. PubMed ID: 9158026
[TBL] [Abstract][Full Text] [Related]
16. Preimplantation factor reduces graft-versus-host disease by regulating immune response and lowering oxidative stress (murine model).
Azar Y; Shainer R; Almogi-Hazan O; Bringer R; Compton SR; Paidas MJ; Barnea ER; Or R
Biol Blood Marrow Transplant; 2013 Apr; 19(4):519-28. PubMed ID: 23266739
[TBL] [Abstract][Full Text] [Related]
17. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation.
Min CK; Maeda Y; Lowler K; Liu C; Clouthier S; Lofthus D; Weisiger E; Ferrara JL; Reddy P
Blood; 2004 Nov; 104(10):3393-9. PubMed ID: 15280194
[TBL] [Abstract][Full Text] [Related]
18. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation.
Hill GR; Cooke KR; Teshima T; Crawford JM; Keith JC; Brinson YS; Bungard D; Ferrara JL
J Clin Invest; 1998 Jul; 102(1):115-23. PubMed ID: 9649564
[TBL] [Abstract][Full Text] [Related]
20. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease.
Alpdogan O; Schmaltz C; Muriglan SJ; Kappel BJ; Perales MA; Rotolo JA; Halm JA; Rich BE; van den Brink MR
Blood; 2001 Oct; 98(7):2256-65. PubMed ID: 11568014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
